ES2104507A1 - Use of gelatin hydrolysate to prepare a pharmaceutical composition intended for the prevention and treatment of hip dysplasia in dogs. - Google Patents

Use of gelatin hydrolysate to prepare a pharmaceutical composition intended for the prevention and treatment of hip dysplasia in dogs.

Info

Publication number
ES2104507A1
ES2104507A1 ES09500449A ES9500449A ES2104507A1 ES 2104507 A1 ES2104507 A1 ES 2104507A1 ES 09500449 A ES09500449 A ES 09500449A ES 9500449 A ES9500449 A ES 9500449A ES 2104507 A1 ES2104507 A1 ES 2104507A1
Authority
ES
Spain
Prior art keywords
dogs
prepare
pharmaceutical composition
composition intended
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09500449A
Other languages
Spanish (es)
Other versions
ES2104507B1 (en
Inventor
Garcia Pilar Quijano
Banos Jaime Melendo
Quilez Purificacion Benavent
Gil Gabriel Espelleta
Riuro Ferran Junca
Riuro Miquel Junca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Masterfarm SL
Original Assignee
Masterfarm SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Masterfarm SL filed Critical Masterfarm SL
Priority to ES9500449A priority Critical patent/ES2104507B1/en
Publication of ES2104507A1 publication Critical patent/ES2104507A1/en
Application granted granted Critical
Publication of ES2104507B1 publication Critical patent/ES2104507B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of gelatin hydrolysate to prepare a pharmaceutical composition intended for the prevention and treatment of hip dysplasia in dogs. The present invention relates to the use of a highly purified gelatin hydrolysate to prepare a pharmaceutical composition intended to be administered to young dogs, principally dogs of those species with greater predisposition to develop hip dysplasia, such as occurs with the German shepherd, Rottweiler and mastiff, among others, with the aim of preventing it, as well as to adult dogs in the first stages of the disease, and also to those which are in the inflammatory phase of said disease.
ES9500449A 1995-03-07 1995-03-07 USE OF GELATIN HYDROLYZATE TO PREPARE A PHARMACEUTICAL COMPOSITION INTENDED FOR THE PREVENTION AND TREATMENT OF HIP DYSPLASIA IN DOGS. Expired - Fee Related ES2104507B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9500449A ES2104507B1 (en) 1995-03-07 1995-03-07 USE OF GELATIN HYDROLYZATE TO PREPARE A PHARMACEUTICAL COMPOSITION INTENDED FOR THE PREVENTION AND TREATMENT OF HIP DYSPLASIA IN DOGS.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9500449A ES2104507B1 (en) 1995-03-07 1995-03-07 USE OF GELATIN HYDROLYZATE TO PREPARE A PHARMACEUTICAL COMPOSITION INTENDED FOR THE PREVENTION AND TREATMENT OF HIP DYSPLASIA IN DOGS.

Publications (2)

Publication Number Publication Date
ES2104507A1 true ES2104507A1 (en) 1997-10-01
ES2104507B1 ES2104507B1 (en) 1998-07-01

Family

ID=8289693

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9500449A Expired - Fee Related ES2104507B1 (en) 1995-03-07 1995-03-07 USE OF GELATIN HYDROLYZATE TO PREPARE A PHARMACEUTICAL COMPOSITION INTENDED FOR THE PREVENTION AND TREATMENT OF HIP DYSPLASIA IN DOGS.

Country Status (1)

Country Link
ES (1) ES2104507B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048516A1 (en) * 1998-03-25 1999-09-30 Masterfarm, S.L. Utilization of gelatine hydrolizats

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772476A (en) * 1986-03-12 1988-09-20 Ralston Purina Company Method for reducing the severity of hip joint laxity in dogs
US4866082A (en) * 1988-04-06 1989-09-12 American Home Products Corporation Inhibition of bone loss by (-)-N-[[(5-chloro-2-benzothiazolyl)thio]phenylacetyl]-L-cysteine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772476A (en) * 1986-03-12 1988-09-20 Ralston Purina Company Method for reducing the severity of hip joint laxity in dogs
US4866082A (en) * 1988-04-06 1989-09-12 American Home Products Corporation Inhibition of bone loss by (-)-N-[[(5-chloro-2-benzothiazolyl)thio]phenylacetyl]-L-cysteine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048516A1 (en) * 1998-03-25 1999-09-30 Masterfarm, S.L. Utilization of gelatine hydrolizats

Also Published As

Publication number Publication date
ES2104507B1 (en) 1998-07-01

Similar Documents

Publication Publication Date Title
BR0008059A (en) Compositions of valdecoxib
BR9713400A (en) Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis.
BR9714517A (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising them and processes to inhibit beta-amyloid peptide release and / or its synthesis by using such compounds
BG101118A (en) Therapeutical compounds
HUP9901144A2 (en) Pharmaceutical compositions containing new associations of clopidogrel and an antithrombotic agent
DE69920757D1 (en) IMMUNE SUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES
DE122010000050I1 (en) SUBLINGUAL OR BUKKALES MEDICINES
BG106030A (en) Pharmaceutical composition
PT782449E (en) MANUFACTURING PROCESS OF HUMIDITY GRANULATION DOSAGE UNITS
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
TR200001982T2 (en) Pharmaceutical shot-release oral dosage form.
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
ATE272628T1 (en) SUBSTITUTED GAMMA-PHENYL-DELTA-LACTONES AND ANALOGUES THEREOF, AND USES THEREOF
FI964332A (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
ATE218581T1 (en) CYCLOSPORINE DERIVATIVE, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION
ATE316794T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LYSOSTAPHIN ALONE OR IN COMBINATION WITH AN ANTIBIOTIC FOR THE TREATMENT OF STAPHYLOCOCCAL INFECTIONS
BR9914631A (en) Tolerance-inducing oral immunological composition for disease prevention and / or treatment and method for disease prevention and / or treatment
FR2705673B1 (en) Compositions comprising amino acid derivatives, processes for their preparation and their uses.
DK1082131T3 (en) Immunoregulator
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
MX9707642A (en) Pharmaceutical agents for the treatment of alzheimer's disease.
BG103512A (en) Substituted pyramidine compounds and their application
DK0719276T3 (en) Estradiol esters with strong oral action as well as pharmaceutical preparations containing them
ES2104507A1 (en) Use of gelatin hydrolysate to prepare a pharmaceutical composition intended for the prevention and treatment of hip dysplasia in dogs.
DK0722325T3 (en) Preparation for the treatment or prevention of herpes

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19971001

Kind code of ref document: A1

Effective date: 19971001

FD2A Announcement of lapse in spain

Effective date: 20150826